Moleculin Secures Australian Patent for Annamycin Formulation Technology
Globe Newswire•12/11/2026•08:37 ET
1
Key Highlights
- ➤Australian Patent No. 2020303572 granted for preliposomal Annamycin lyophilizate preparation
- ➤Moleculin’s Annamycin patent portfolio spans granted or allowed rights across 10 jurisdictions
- ➤South Africa patent application accepted; South Korean and other applications remain pending
- ➤Moleculin requires significant additional financing to conduct planned clinical trials
Expert Statements
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
“Securing this patent in Australia represents another step in our efforts to build a strong international intellectual property position around Annamycin”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
“Our formulation technology is an important component of Annamycin’s development, and protecting this technology across international markets supports our broader intellectual property strategy.”
Patent strengthens intellectual property protection for preparation of preliposomal Annamycin lyophilizate
HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced the grant of an Australian patent covering the preparation of preliposomal Annamycin lyophilizate, strengthening the Company’s intellectual property protection for a key aspect of Annamycin’s formulation technology.
Get started
Create a free account to read the full story.